anonymous
Guest
anonymous
Guest
Rumblings of a buyout at a 75% premium at $84
Gonna get gobbled up and many will be axed…not some!
I got something for you to gobble on!
it may not be the girth that you are used to taking but it’s eliteSorry tiny…4 inch mushrooms not my thing!
it may not be the girth that you are used to taking but it’s elite
Nothing elite about your little meat puppet! more like subpar just like Assome
you didn’t get the job?? NO MEAT FOR YOU!
Enjoy your short lived gig, little meat puppet!!
Citing two sources tasked with formulating coverage decisions for large plans, BofA analysts led by Jason Gerberry noted that after pricing Auvelity above the MDD drugs approved on monotherapy studies, the company would have to offer deep discounts to improve uptake.
Given the promotion-sensitive nature of the MDD category due to its large prescriber base, analysts expect Auvelity to underperform during the launch despite the sizable market opportunity.
lol @ the Trintellix rep. Hurry, the local library will close soon so get your comments in quick.
We shall see who laughs last…Assome tool!
You got picked on a lot growing up, yes?[/QUOTE
Notice how you’re always deflecting to juvenile like comebacks- grow some balls and face reality…you work for a shitty start up run by castaways from 3rd tier companies ( Avanir, UCB, etc ) soon to be taken over by a real pharma company! Sleep on that…
Aplenty? Hmmm. Sounds a little bit like Aplenzin. Heard of it? No one has. That’s because Wellbutrin Jr. has been attempted before…poorly.
Aplenty? Hmmm. Sounds a little bit like Aplenzin. Heard of it? No one has. That’s because Wellbutrin Jr. has been attempted before…poorly.